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The normal architecture and biologic function of the kidney
depends on an integrated network of cellular and extracellular
matrix interactions. The extracellular matrix, in addition to its
role in the organization of renal tissue, also provides structural
dimensions for fluid and protein movement through which
physiologic systems operate to modify the filtration of ions and
macromolecules, or to alter the size, proliferation and biological
expressions of renal cells [1]. Thus, the renal extracellular
milieu constitutes the primary communication and signal proc-
essing pathway for the constituents of surrounding tissue.
Although poorly characterized and poorly understood, recent
advances in molecular and cellular biology have provided a
variety of new experimental approaches from which to further
analyze this subject matter [2—5].
Several highly dynamic processes are thought to modulate
the integrity of the extracellular matrix as well as its associated
cellular components. Among these processes are cell-cell con-
tact [6] and cell-matrix adhesion [7] mediated, in both spatial
and temporal circumstances, by an increasingly abundant set of
matrix-relevant cytokines. These interactive events, and their
regulatory cascade, provide for the elegant remodelling of
structural tissues within developing kidney, their homeostatic
maintenance and turnover in adult life, as well as their obliter-
ation during prolonged inflammation when regenerative pro-
cesses are no longer capable of recreating naive tissues.
Any alteration in the composition and structure of the extra-
cellular matrix is, therefore, likely to have important conse-
quences for the function of the nephron, and kidney, in general
[8]. Such changes may accompany renal injury, or appear as
sequelae of a variety of etiologic events, including deviation
from the genetic wild-type, new metabolic disturbances, altered
immunological responses, or the use of pharmaceuticals.
Perhaps the most commonly recognized disturbance in the
topography of extracellular matrix resulting from prolonged
injury is fibrosis (Table 1). This represents the major lesion of
end-stage renal disease, and is characterized by the elaboration
of a variety of autocrine and paracrine factors affecting several
cellular components, their cellular proliferation and migration,
and their net contribution to the deposition of matrix compo-
nents, particularly the interstitial collagens.
The homeostatic role of the fibrogenic process is difficult to
evaluate because it provides structural success mixed with
architectural failure. On one hand, it represents a compensatory
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mechanism initiated to maintain the structural integrity of
tissue, to contain the deleterious consequences of inflammatory
reactions, and to recruit and stimulate cells necessary for the
repair of damaged tissue and subsequent restoration of func-
tion. Fibrogenesis, however, can also reflect the relentless
sequelae of chronic inflammatory events. The resultant disrup-
tion and destruction of tissue architecture, and the subsequent
loss of function at both local and distant sites within the kidney
can have widespread clinical implications. Progressive fibro-
genesis, therefore, can be viewed as a permissive extension of
normal restorative processes which have deviated to remodel
tissue in an aberrant fashion.
Oddly enough, despite their significant clinical impact, fibro-
genic mechanisms operating locally in the kidney are not
particularly well understood at the present time. On a compar-
ative basis, a more informative literature exists for other organ
systems, particularly the liver, lung, and skin [9—11] where
several experimental paradigms have been extensively ex-
ploited. There is a need for a more thorough comprehension of
the regulatory mechanisms governing fibrogenesis within the
nephron mass. In particular it may be necessary to identify and
characterize the fibrogenic response both from the perspective
of the tubulointerstitium and the glomerulus, where major focus
has been traditional. The tubuloinierstitium takes on signifi-
cance in these matters, not only because of its more extensive
spatial involvement, but also because of a close correlation
between the compromise of renal function and the alteration in
the tubulointerstitial substance [12]. In the following review the
general mechanisms of fibrogenesis will be discussed and an
attempt to identify those components and factors which espe-
cially participate in tubulointerstitial fibrogenesis will be made.
Composition, formation, and pathology of the
tubulointerstitium
Composition
The mature tubulointerstitium is heterogeneous with respect
to cellular constituents, matrix components, and biochemical
functions [13]. In the outer cortical levels, the tubulointersti-
tium is spatially surrounded by the basement membranes of
Bowman's capsule, the vascular beds, and the tubules. In
general, basement membranes are highly ordered structures
consisting of several integrated macromolecules in close juxta-
position with their respective cellular elements. Among the
common components in or surrounding basement membranes
are types IV and V collagens, laminins, nidogen, entactin,
fibronectin, heparan sulfate proteoglycans as well additional
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glycoproteins [14, 15]. Besides creating anatomical barriers
restricting both the flow of molecules and the migration of cells,
basement membranes also appear to participate in the regula-
tion of cell function [16]. While all of these components are
synthesized by their surrounding epithelial or endothelial parent
cells, it should also be appreciated that the distinct phenotype,
and functional repertoire of each of the differentiated cells
collectively imposes both a quantitative and qualitative blend
on the compositional character of their local surrounding base-
ment membranes and their interstitial attachments [17]. Thus,
the extracellular environment can be viewed as a collective
group of heterogeneous microenvironments.
Because of the close apposition of the basement membranes
in the cortex, the interstitium, at this level, is sparse and not
well characterized. At other levels progressing along the neph-
ron toward the renal medulla, however, the interstitium be-
comes increasingly more complex in both extent and cell
composition [18]. Among the additional cells found here are
interstitial fibroblasts, mononuclear cells, and morphologically
distinct interstitial cells of three types [19]. The precise func-
tions of these latter cells have yet to be determined and their
roles in fibrogenesis remain speculative. The interstitial archi-
tecture is comprised of a lattice of stranded material, containing
types I and III collagens in addition to fibronectin, noncollage-
nous glycoproteins and proteoglycans [3, 20]. Studies on mu-
rifle interstitial fibroblasts demonstrate that, although capable
of synthesizing collagens of types I, III, IV and V, their
production of these individual components may be distinct from
fibroblasts found in other sites [21]. It would be expected that
further characterizations might reveal that the composition of
interstitial matrix represents a variable mixture of elements
synthesized by a phenotypically heterogeneous population of
cells whose regulation will also be distinct. This variation in
composition of the renal interstitium thus potentially imposes a
high degree of complexity on models of fibrogenesis.
Formation
The composition and functional repertoire of the mature renal
interstitium is derived from dynamic processes originating in
early development. Several reviews are available describing the
present understanding of the processes involved in renal orga-
nogenesis [2, 3, 22], and a detailed description is beyond the
scope of this discussion. However, the following brief summary
highlights many of the processes which may be potentially
recapitulated during the fibrogenic process.
The metanephric mesenchyme is induced by the ureteric
epithelial bud to undergo differentiation into the structures of
the renal tubules. One significant feature that distinguishes the
tubule epithelium is, therefore, that it is mesenchymally derived
and may possibly share some phenotypic characteristics with
other similarly derived cells, such as fibroblasts. The induction
process has several features including cell-cell contact and
cell-matrix adhesion which are intimately involved in epithelial
formation and differentiation. Prior to induction several extra-
cellular matrix proteins are secreted, including types I and III
procollagens, fibronectin, and laminin [23, 24]. There is evi-
dence that these collagens can modulate the expression of the
differentiating epithelial matrix [25]. Cell adhesion is contrib-
uted by cell-surface molecules including, but not limited to,
E-cadherin [26], and N-CAM [27]. The expression of these
components is spatially and temporally regulated in a distinct
fashion. Upon induction and differentiation of mesenchyme to
epithelium, there is a gradual reduction in type I and III
collagens, and N-CAM with replacement by type IV collagen,
E-cadherin, and transiently, laminin A [28]. Heparan sulfate
proteoglycans also appear at this time. Collectively these
events correspond to the formation of the epithelial basement
membranes. A small portion of the mesenchyme, however,
does not differentiate, and retains the capacity to synthesize
interstitial collagens and fibronectin [29]. The cells in the
mature interstitium derived from this latter pool of mesenchy-
mal cells are not known at present, but they represent a
potentially important component in models of fibrogenesis. In
addition, a unique glycoprotein, tenascin, is transiently ex-
pressed at this time, and recent information strongly suggests
its induction is modulated by the developing epithelium [29].
Although largely absent in adult tissues, this molecule can
reappear during wound repair [301, in the context of new
epithelial tumors [311, as well as provide immunomodulatory
effects at the level of cell adhesion on several immune cell types
[321. It, therefore, may be an important participant in fibrogenic
processes.
The above cell dynamics, and their influence on the expres-
sion of extracellular matrix, serve to underscore the extensive
plasticity of the extracellular matrix. While the extent and
dramatic nature of these processes during embryogenesis is not
fully recapitulated in the normal maintenance of the interstitium
in the mature organ, the pathobiology of fibrogenesis likely
draws on a large portion of this potential plasticity in the
expression of matrix products and cellular behavior.
Pathology
An examination of the literature on the pathogenesis of both
primary and secondary tubulointerstitial disease indicates, in
chronic forms, that the expression of fibrotic lesions usually
maps in a concordant fashion with declining renal function [33].
Several studies have made some attempt to define the nature of
the components of extracellular matrix which accumulate in a
variety of experimental and human nephropathies. In experi-
mental glomerulonephritis, tubulointerstitial fibrosis ultimately
ensues as glomerular disease progresses. In membranous
nephropathy, for example, the kidneys eventually develop both
glomerulosclerosis and tubulointerstitial fibrosis after 35 weeks
[34]. The predominant type of collagen in the tubulointerstitium
is type III. In contrast, in a rabbit model of crescentic glomer-
ulonephritis, the resultant tubulointerstitial fibrosis was com-
prised of both types I and types III collagen by immunofluo-
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rescence [35]. An examination of biopsy material from patients
with a variety of chronic renal diseases exhibiting definitive
fibrosis reveals a distinct deposition of fibronectin along the
interstitial surface of the tubular basement membrane [36].
Diabetes mellitus is also associated with tubulointerstitial fi-
brosis and collagen deposition [37]. Drugs such as cyclosporin
A can also reduce glomerular filtration rate, decrease renal
plasma flow, and with chronic use, produce histopathologic
changes in kidneys suggestive of tubulointerstitial injury ac-
companied by focal glomerulosclerosis [381. This tubulointer-
stitial injury has also been studied in rats treated long term with
cyclosprorin A. Early morphologic evidence of cyclosporin A
nephrotoxity consists of isometric vacuolization and loss of
brush border detected in the proximal tubular cells followed by
a peculiar lesion in distal tubular cells due to glycogen accumu-
lation. Light microscopy in these cyclosporine-treated rats
reveals limited areas of interstitial fibrosis mainly with a
perivascular distribution [39]. It has also been observed in
patients with scleroderma that the ratio of type 111/I collagen
increases, and stays elevated, during the course of the disease,
unlike many other non-renal fibrosing events [40]. And biopsy
material from patients with membranoproliferative glomerulo-
nephritis, containing crescents in association with vasculitis,
also demonstrate an excess of type III collagen [411.
Our knowledge, however, of other components of the extra-
cellular matrix, and how they change during the course of the
tubulointerstitial disease in vivo, in both human and experimen-
tal animal models, is very rudimentary. Clearly, this area of
investigation will receive greater attention, since comprehen-
sive and definitive studies here would provide a much needed
framework for detailed biochemical and cellular studies in vitro.
The fibrogenic process
Experiments examining the fibrogenic process in the tubu-
lointerstitium from either a cellular, immunologic, biochemical,
or molecular perspective are currently underway in several
laboratories. Useful correlative models for fibrosis, however,
have already been established in the liver [9] and other organs
[42]. Although organizational details surrounding interstitial
fibrogenesis are certainly going to vary from model to model,
several common and general features can be ascertained at
present. First, fibrogenesis is usually a response to an inflam-
matory process [9]. This is certainly the case with trauma-
induced injury where the presence of mononuclear cells have
been observed to be a prerequisite for the elaboration of fibrotic
tissue [43]. Secondly, fibrogenesis is a time-dependent phenom-
enon, requiring a finite period for activation and elaboration.
Thirdly, the process is regulated by a host of paracrine factors,
with pleiotropic effects, secreted by both immune and organ-
resident cells.
Fibrogenesis can be arbitrarily divided into three general
phases. The distinction, of course, is somewhat artificial, since
many of the underlying processes proceed in parallel with one
another. Phase one represents the induction of conditions
necessary for the establishment of active fibrogenesis and
matrix remodelling. Phase two reflects the deposition of matrix,
and phase three provides a resolution in which there is an
attenuation of the active process.
Phase one: Induction
The establishment of permissive conditions which extend the
deposition of extracellular matrix is one of the more complex
and highly variable components of the fibrogenic process. The
variability is certainly responsible for some of the multi-dimen-
sional features of tubulointerstitial fibrosis. The quantitative, as
well as qualitative, nature of this response can be evaluated
from two perspectives: one is the breadth of stimulatory and
inhibitory factors which act on those cells, and the other is the
characteristics of the discrete target cells which express the
fibrotic matrix.
Data from other experimental systems, particularly murine
hepatic fibrogenesis, provide some perspectives into mecha-
nisms which may operate in the tubulointerstitium. Several
cytokines elaborated by circulating cells recruited into the
inflammatory site may activate proliferative and migratory
fibrogenic responses in resident cells. While several cytokines
with stimulatory effects may be present, premier among these is
transforming growth factor beta (TGF/3) whose inflammatory,
immunomodulatory, and regulatory roles as a matrix-relevant
gene product are becoming increasingly recognized [441. In
vascular trauma, platelets aggregate and produce large amounts
of platelet-derived growth factor (PDGF), a potent chemoat-
tractant for fibroblasts [45], and TGF/3, a strong stimulant to
fibroblast proliferation [46]. Activated macrophages play a
principal role in fibrogenesis by also releasing a number of
soluble factors. Among these, PDGF [471 and TGF/3 [48] are
released in substantial quantities, as is fibroblast growth factor
[49]. Furthermore, interleukin-l [50] and TNFa [51] are also
secreted but may have inhibitory effects on fibroblast growth,
presumably through the modulation of intrinsic prostaglandin
synthesis [52]. T-lymphocytes recruited into the site of inflam-
mation release growth factors which can also stimulate fibro-
blast proliferation [9, 53, 541, especially T-helper cells in the
context of interstitial nephritis [55]. However, the role of 7IFN
in recruitment and proliferation of fibroblasts at present is
unclear [9].
Fibroblast growth, proliferation, and motility can also be
modulated by additional pathways. Activation of complement
releases a fragment from C5 which is chemotactic for fibroblasts
[56]. Cleavage of fibronectin [57] and types I and III collagens
[58] can also enhance cell motility. Proteases secreted by
activated macrophages can participate in such cleavages, and
subsequent phagocytosis of extracellular matrix framents can
form a pathway through which the fibroblast may be easily
attracted 159]. In addition, activated fibroblasts, themselves,
can secrete TGF/3 [60] as well as collagenases [61], and stromel-
ysin, a metalloproteinase which has multiple matrix targets [62],
thereby enhancing their migratory progress through the inter-
stitium.
In most systems the phenotype of the only cell thought to be
active in fibrogenesis is the resident or recruited fibroblast [63].
Conclusions such as this rest on historical precedent balanced
by two somewhat erroneous assumptions. One assumption is
that fibroblasts make types I and III procollagens, to the
exclusion of type IV, and that the cells, themselves, serve few
other purposes. The second assumption is that epithelium
cannot produce interstitial collagens. Both of these assumptions
appear to be fundamentally incorrect [64, 65].
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The interstitium is inhabited by both fibroblasts and abundant
numbers of tubuloepithelial cells. Fibroblasts are not found, nor
can they be reliably grown out of the glomerular tuft (unpub-
lished observations). Tubulointerstitial fibroblasts have been
cultured and have been shown to secrete abundant amounts of
types I, Ill, and also IV procollagens [21]. However, their
procollagen synthetic response to immune-relevant cytokines is
quite different from the response observed in skin fibroblasts of
the same genotype. The heterogeneity among fibroblasts har-
vested from different microenvironments serves to limit the
extent to which data can be extrapolated from other experimen-
tal systems and applied to renal fibrogenesis.
Murine proximal tubular cells, like the tubulointerstitial 11-
broblast, have been demonstrated to secrete interstitial procol-
lagen types I and III, in addition to basement membrane
procollagens types IV, V, and laminin [64]. Furthermore, the
synthesis of these collagens can be modulated by several
growth factors and cytokines [66]. In addition, these cells can
express the MHC class II molecule on their surface, providing
a mechanism for the direct involvement of antigen presentation
to T-lymphocytes with subsequent production of lymphokines
that can sequentially modulate the production of extracellular
matrix material [67]. Epithelial cells derived from rat kidney can
also be shown to secrete type I and III collagens whose
production can be upregulated by growth factors [68]. The
intriguing possibility that a primary source of fibrotic substance
is the tubular epithelium awaits further study, but given its
position as the predominant renal cell type, a featured role for
this cell is quite likely.
Although considerably more investigation will be required to
fully elucidate many of these processes in the tubulointerstitial
microenvironment, it can be appreciated that the recruitment of
additional inflammatory cells, and their secretory factors, may
both stimulate and inhibit fibroblast motility and proliferation.
This will likely create a variable response, highly dependent on
both quantitative levels of each as well as their particular
effects. A balance between such factors could lead to a well
regulated repair of tissue or, in contrast, lead to fibrosis. Since
most of these factors operate over short distances, local gradi-
ents could significantly alter the outcome of competing mecha-
nisms.
Phase two: Matrix deposition
Throughout most forms of fibroplasia, fibroblasts undergo a
variety of morphological changes [691. Following the acquisi-
tion of a phenotype capable of producing substantial quantities
of collagen, fibronectin and proteoglycans, fibroblasts then
become competent to initiate matrix deposition. In most studied
systems fibronectin synthesis appears first [70]. This fibronectin
matrix may provide a scaffold for the deposition and fibrillo-
genesis of interstitial collagens [10]. Type III collagen is often
deposited initially in higher ratios, but as fibrogenesis proceeds,
type III collagen decreases relative to type 1191. The nature of
this switch is unclear.
The regulation of matrix proteins is complex and involves
several potential levels of control. For collagens, these controls
may be in the areas of transcription, translation, post-transla-
tion modifications, assembly of fibrils, secretion, deposition,
fiber assembly and cross linking 1711. With few exceptions, the
effects of most of the fibrogenic factors at each of the levels are
unknown. Interleukin- 1 (IL-I) stimulates transcription of inter-
stitial collagens, however, conflicting results have been ob-
tained for its effect on collagen secretion [9]. Furthermore,
PGE2 or IL-l seems to promote the synthesis of type III
collagen versus type 11721. yIFN inhibits collagen transcription
in a variety of fibroblasts 1731. Conversely, TGF stimulates the
transcription of fibronectin and collagen type I through the
binding of a nuclear factor (NF-l) to regulatory elements in the
promoters of these genes [66, 74]. Interestingly, several other
genes contain the same element, although their coordinate
regulation with matrix proteins in fibroblasts is not known 1601.
TGF/3 also stimulates fibronectin matrix assembly [101. This
pluripotent factor has also shown to increase collagen type III
synthesis in rat renal epithelial cells 165, 68], thus apparently
correlating with limited in vivo data. In contrast, type I collagen
appears to be downregulated in a tubular cell line, the MCT
cells [64]. To further extend TGFf3's effects, collagenase and
stromelysin, members of the metalloproteinase family respon-
sible for the degradation of the extracellular matrix are tran-
scriptionally inhibited by this factor [75, 76]. In addition syn-
thesis of a metalloproteinase inhibitor is augmented by TGFJ3
[62]. Thus, a reciprocal activity of TGF is defined, leading to
the net deposition of matrix constituents, and furthermore,
suggests its significant role in the matrix formation in the
tubulointerstitium.
MCT cells secrete types IV and V procollagens and laminin
(as expected of tubule epithelium), but also small amounts of
interstitial types I and III procollagens [64]. Secretion of type
IV procollagen by the cells can be virtually eliminated by
treatment with a helper T cell-secreted heterodimer (ThF) that
binds 3M-l [77], the glycoprotein antigen secreted by this
proximal tubular epithelium [78]. ThF was originally character-
ized for its ability to induce nephritogenic T cells out of naive
splenic cell populations when co-cultured within interleukin-2
and the 3M- 1 antigen of the autoimmune interstitial nephritis
[79]. In contrast to type IV collagen expression, the secretion of
type I procollagen by the MCT cells is slightly stimulated by
ThF [77]. The level of control of this secretion is transcriptional
in that ThF inhibits the expression of type IV procollagen
mRNA and stimulates the expression of type I procollagen
mRNA. Moreover, in kidneys from mice immunized to produce
the experimental autoimmune interstitial nephritis, there is
decreased type IV collagen mRNA and product, and increased
type I collagen mRNA and product in fibrogenic tubulointersti-
tial sections infiltrated by helper T cells. Interestingly, in such
kidneys there is also decreased expression of the 3M-l antigen
gene [80]. Transcriptional control of target epithelial genes by
3M-l-specific factors in this immune-mediated disease is not
unprecedented in that antibodies against the 3M- 1 target antigen
decrease the transcription rate for class II MHC in vitro and in
vivo [67]. With decreased class II expression in vivo, there is
abrogation of interstitial nephritis mediated by class II re-
stricted, 3M-l reactive CD4+ effector T cells. Finally, the
interactions between the immune system and the epithelium in
anti-3M-I disease may not simply be "one-way" since MCT
cells can directly activate 3M-l reactive helper T cells, perhaps
in part through secretion of an interleukin-l like molecule [811.
Thus, the emerging view of target epithelium, from these
studies, is that there is a dynamic interplay between various
limbs of the immune system and the recognized parenchymal
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target epithelial tissue, which clearly can regulate antigen,
MHC and matrix gene expression. During immune-activated
fibrogenesis in interstitial injury, the target epithelium repre-
sents a centrally active element capable of activating T cells
directly, like a classic antigen presenting cell, regulating antigen
and the expression of MHC genes, and thus immune recogni-
tion of itself indirectly in response to a variety of cytokines,
some of which are 3M-i antigen-specific, and finally, secreting
collagen components which appear as part of the final, altered
fibrosing substance.
Patterns of tubular epithelial cell matrix secretion may be
pleiomorphic depending on the type of disease causing fibro-
genesis. For example, the secretion and transcription of both
types I and IV procollagen in MCT cells is stimulated by
elevating the media glucose from 100 to 450 mg/dl 1821. Such an
increase in the glucose concentration also induces hypertrophy
in MCT cells, as determined by cell size and protein content per
cell. Moreover, the high glucose decreases proliferation in the
MCT cells. Thus two diseases associated with tubulointerstitial
fibrosis, namely immune-mediated anti-3M-i disease and dia-
betes mellitus, can have a different pattern of tubulointerstitial
fibrosis as assessed by secretion of procollagens by the proxi-
mal tubular epithelium. In the immune anti-3M-i disease, type
IV secretion is profoundly decreased, whereas type I is in-
creased, and in the diabetic model, the secretion of both types
I and IV procollagens are increased by elevating the ambient
glucose. Besides heterogeneity in the fibrogenic response of
proximal tubules in different diseases, there may be a variable
response to immunologic or metabolic derangements of renal
tubular cells from other anatomic compartments of the tubule.
Phase three: Resolution
Perhaps one of the more obscure aspects of fibrogenesis is
how the response is abrogated during the attenuation of injury.
Several mechanisms appear to be involved. Most obvious is the
resolution of the inflammatory response. For example, the
repair of site of trauma will reduce macrophage activation and
subsequently attenuate the elaboration of factors promoting
continued synthesis of matrix components. Reduction in the
level of TGF/3, for example, will reciprocally permit the in-
creased synthesis of collagenase and stromelysin in concert
with decreasing the highly expressed levels of collagen and
tissue inhibitors of metalloproteinase. The promotion of colla-
genolytic activity thus can begin the restoration of the tissue
[83]. Another possibility is an intriguing study in normal rat
kidney cells. High concentrations (picomolar) amounts of
TGFI3 apparently have an inhibitory effect on the proliferation
of these cells grown on collagen matrices, but not when cells are
grown on fibronectin [84]. Apparently this provides a means, in
addition to the local restriction of factors, of focally containing
the fibrotic response. In similar fashion TGF/3 appears to have
an immunosuppressive role also [44] by inhibiting the growth
and proliferation of both T and B lymphocytes. Although
growth inhibition restricts the extent of the fibrogenic response,
it serves only to dampen an ongoing response.
Other immunosuppressive possibilities include the involve-
ment of suppressor T lymphocytes. Such networks have been
characterized in autoimmune interstitial nephritis where abro-
gation of an operative suppressor network leads to inflamma-
Table 2. Key events during fibrogenesis
•Phase 1—Induction
Activation of macrophages and elaboration of cytokines (TGFp,
IL-i, PDGF, TNFr)
Recruitment of immune cells (B-cells, T-cells, eosinophils) and
elaboration of cytoplasmic factors (IL-2, yIFN)
Recruitment, stimulation of motility, and proliferation of fibroblasts
Dissolution and phagocytosis of matrix
Stimulation of tubular epithelium
Phase 2—Matrix deposition
Maintenance of a chronic inflammatory state
Fibronectin, collagen types III and I synthesis, secretion, and
deposition
•Phase 3—Resolution
Removal or suppression of inflammatory state
Reduction in levels of matrix synthesis
Stimulation of matrix proteolysis
tion and fibrogenesis [851. Restoration of the suppressor net-
work thus leads to restriction of the fibrogenic response [861.
Summary
With regard to tubulointerstitial fibrogenesis we are left with
a variety informational gaps regarding nearly all aspects of this
clinically important process. Table 2 summarizes a generalized
version of fibrogenesis based primarily on investigations in
other organs. Extrapolation of data obtained with other fibro-
genic systems is useful, but only in so far as it motivates us to
adapt and test many of the experimental principles within in the
context of the kidney. This begins with a comprehensive
examination of the in vivo state, the establishment of adequate
animal models, and the dissections of the process in vitro. Key
areas for the future are the characterization of the signals
involved, the cellular responses to these signals, and the
variations in interactions produced by differing inciting fibro-
genic conditions.
Reprint requests to Dr. Gerald S. Kuncio, Renal-Electrolyte Section,
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